0 119

Cited 25 times in

Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission

Authors
 Se-Hoon Lee  ;  Mark H. Lee  ;  Je-Hwan Lee  ;  Yoo Hong Min  ;  Kyoo-Hyung Lee  ;  June-Won Cheong  ;  Jeeyun Lee  ;  Keon Woo Park  ;  Jung Hun Kang  ;  Kihyun Kim  ;  Won Seog Kim  ;  Chul Won Jung  ;  Seong-Jun Choi  ;  Jung-Hee Lee  ;  Keunchil Park 
Citation
 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, Vol.11(2) : 122-128, 2005 
Journal Title
 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 
ISSN
 1083-8791 
Issue Date
2005
MeSH
Adolescent ; Adult ; Antigens, CD34/analysis* ; Bone Marrow Cells/cytology* ; Bone Marrow Transplantation* ; Disease-Free Survival ; Female ; Humans ; Leukemia, Myeloid, Acute*/mortality ; Leukemia, Myeloid, Acute*/therapy ; Leukocyte Count ; Male ; Middle Aged ; Recurrence ; Siblings ; Tissue Donors* ; Transplantation, Homologous ; Treatment Outcome
Keywords
Allogeneic BMT ; Acute myelogenous leukemia ; CD34+ cell dose
Abstract
Allogeneic stem cell transplantation (ASCT) has improved the outcome of acute myelogenous leukemia (AML). To further improve the treatment outcome of ASCT in AML, finding a modifiable prognostic factor is mandatory. We evaluated the effect of CD34+ cell dose on survival in allogeneic bone marrow transplantation (BMT) from HLA-matched sibling donors for AML patients in first complete remission (CR1). The 99 patients included in our analysis were classified into high CD34+ cell dose group (CD34+ cells ≥ 2.5 × 106/kg) and low CD34+ cell dose group (CD34+ cells < 2.5 × 106/kg). The high CD34+ cell dose patients had better overall survival (5-year overall survival rate, 75% ± 6% vs 52% ± 9%; P = .01) and leukemia-free survival (5-year leukemia-free survival rate, 70% ± 6% vs 44% ± 9%; P = .04). CD34+ cell dose was the only independent prognostic factor in overall survival and leukemia-free survival. The high CD34+ cell dose group had a lower relapse incidence with a borderline statistical significance (5-year relapse rate, 27% ± 6% vs 50% ± 10%; P = .09). There were no differences in the engraftment of neutrophil and platelet, grade II-IV acute graft-versus-host disease (GVHD), extensive-stage chronic GVHD, and transplant-related mortality between the high and low CD34+ cell dose groups. We confirmed that high CD34+ cell dose favorably affects the outcomes in allogeneic BMT for AML. The effort to attain a high CD34+ cell dose should be pursued during bone marrow harvest in allogeneic BMT for AML in CR1.
Full Text
http://www.sciencedirect.com/science/article/pii/S1083879104006007
DOI
10.1016/j.bbmt.2004.11.018
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
Cheong, June-Won(정준원) ORCID logo https://orcid.org/0000-0002-1744-0921
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/151162
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse